What we invest in:

• NeuroAIBrain data, connectomics, and foundation models. AI that learns from the brain, and AI that helps understand it.
• Neurotech & BCIImplants, wearables and neural interfaces that read and write to the brain and nervous system.
• Precision NeuroShifting from population-wide care to approaches built on each patient's profile.
• New ModalitiesRNA, gene, cell therapies, and delivery technologies that transcend conventional small molecules.
• Human AugmentationTechnologies that improve cognition, focus, mood, and sleep, and keep the brain healthy.
• Platforms & TherapeuticsHorizontal platforms, AI-driven discovery, and novel compounds.
• Digital Health & TherapeuticsApps, wearables, and platforms that help patients treat, prevent, or manage disease.
• NeurometabolismHow drugs, diet, exercise, and gut microbiota affect metabolism and health.
• UnchartedBuilding something that doesn’t fit these categories? If it’s frontier, we want to hear from you.

Companies we back:

• Aerska, RNAi medicines to treat, delay, and prevent neurodegeneration.
• Ancilia, CRISPR for live biotherapeutics and bacterial products.
• Beckley Psytech, short duration, rapid-acting psychedelics. Acquired.
• Bexson Biomedical, novel ketamine formulations for pain and mental health.
• Bloom Science, microbiome therapeutics platform for neurological disease.
• Bright Minds, next-generation psychedelics for brain and mental health. IPO.
• Delix Therapeutics, non-hallucinogenic versions of psychedelic compounds.
• Freedom Biosciences, next generation psychedelic therapeutics.
• Gilgamesh Pharmaceuticals, clinical-stage neuroscience biotech. Acquired.
• Humans Anonymous, anonymous audio spaces for mental health.
• Imyoo, patient-centric immune biodiscovery platform.
• Iris Medicine, small-binding RNA medicine for neurodegenerative diseases.
• Jimini Health, AI-assisted therapy tool for therapists.
• Journey Clinical, empowering mental health professionals to offer psychedelic therapy.
• Maya Health, data intelligence platform for psychedelic therapy.
• Mindstate Design Labs, next-generation psychedelic-inspired medicines.
• Motif Neurotech, minimally invasive bioelectronic solutions for the brain.
• Neurode, non-invasive neurostimulation starting with ADHD.
• Remepy, hybrid treatments combining traditional drugs with digital therapeutics.
• Sanmai, transcranial focused ultrasound for mental health.
• Sculpta Bio, programmable RNA splicing medicine for complex brain diseases.
• Siggy, AI psychiatrist.
• Tactogen, drug development platform for gentler and safer entactogens.
• Terran, drug discovery platform for CNS and mental health.
• Tripp, VR/AR platform for meditation and psychedelic-like experiences.
• And in stealth: biohybrid BCIs, wearable neurotech, brain data for AI, polypharmacology, organelle models, neuroinflammation biologics, patient data for AI models, a neuron-protective modality, cancer behavioral health, and a mental health marketplace.

Who we are:

• Matias Serebrinsky, General Partner & Co-Founder. Previously led NVIDIA's accelerator for AI startups, Inception North America, and co-founded CookUnity ($1B ARR). LinkedIn, X.
• Greg Kubin, General Partner & Co-Founder. Previously co-founded HelloSponsor, a SaaS platform (AngelPad '15). Ex-Morgan Stanley, Viacom. LinkedIn, X.
• Danny Carbonero PhD, Associate. Ex-Breakout Ventures. PhD in Computational Neuroscience and Biomedical Engineering, Boston University. LinkedIn.
• Dina Burkitbayeva MBA/MS, Co-Founder. CEO, Freedom Biosciences.
• Martina Galdos, Operations Lead.
• Tim Gardner PhD, Venture Partner. Chair of Bioengineering, University of Oregon. Founding member of Neuralink.
• Negin Mokhtari PhD, Venture Partner. Luma Group, ex-Bioluminescence and Genoa Ventures.

Advisors:

• John Krystal MD, Chief of Psychiatry, Yale-New Haven.
• Graham Pechenik JD, patent attorney.
• Jacob Robinson PhD, CEO, Motif Neurotech. Professor, Electrical and Computer Engineering, Rice University.
• Chrystal Mavros PhD, microbiology, Columbia University.
• Alex Amen PhD, BridgeBio, Doudna lab.